IM Cannabis (IMCC) Competitors $2.44 +0.18 (+7.96%) Closing price 03:58 PM EasternExtended Trading$2.45 +0.01 (+0.41%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCC vs. QNTM, ATNM, UNCY, ANVS, PRLD, SLGL, STTK, VTVT, MAAQ, and ABVCShould you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Quantum Biopharma (QNTM), Actinium Pharmaceuticals (ATNM), Unicycive Therapeutics (UNCY), Annovis Bio (ANVS), Prelude Therapeutics (PRLD), Sol-Gel Technologies (SLGL), Shattuck Labs (STTK), vTv Therapeutics (VTVT), Mana Capital Acquisition (MAAQ), and ABVC BioPharma (ABVC). These companies are all part of the "pharmaceutical products" industry. IM Cannabis vs. Its Competitors Quantum Biopharma Actinium Pharmaceuticals Unicycive Therapeutics Annovis Bio Prelude Therapeutics Sol-Gel Technologies Shattuck Labs vTv Therapeutics Mana Capital Acquisition ABVC BioPharma IM Cannabis (NASDAQ:IMCC) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk. Which has preferable earnings and valuation, IMCC or QNTM? IM Cannabis has higher revenue and earnings than Quantum Biopharma. IM Cannabis is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIM Cannabis$39.44M0.32-$7.72M-$0.54-4.52Quantum BiopharmaN/AN/A-$14.20M-$14.02-1.23 Does the media prefer IMCC or QNTM? In the previous week, IM Cannabis and IM Cannabis both had 1 articles in the media. IM Cannabis' average media sentiment score of 1.87 beat Quantum Biopharma's score of 0.94 indicating that IM Cannabis is being referred to more favorably in the media. Company Overall Sentiment IM Cannabis Very Positive Quantum Biopharma Positive Do insiders & institutionals hold more shares of IMCC or QNTM? 7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 5.9% of IM Cannabis shares are held by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, IMCC or QNTM? IM Cannabis has a beta of 2.2, indicating that its share price is 120% more volatile than the S&P 500. Comparatively, Quantum Biopharma has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Is IMCC or QNTM more profitable? Quantum Biopharma has a net margin of 0.00% compared to IM Cannabis' net margin of -4.19%. IM Cannabis' return on equity of -59.80% beat Quantum Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets IM Cannabis-4.19% -59.80% -5.15% Quantum Biopharma N/A -270.22%-131.87% SummaryIM Cannabis beats Quantum Biopharma on 8 of the 11 factors compared between the two stocks. Get IM Cannabis News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCC vs. The Competition Export to ExcelMetricIM CannabisMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.81M$10.59B$5.76B$9.84BDividend YieldN/A1.86%3.95%4.03%P/E Ratio-4.5221.7131.3126.60Price / Sales0.3230.36461.61121.39Price / CashN/A24.9437.7659.36Price / Book4.363.5110.026.67Net Income-$7.72M$210.11M$3.27B$265.59M7 Day Performance11.93%5.20%3.17%3.42%1 Month Performance-12.86%11.64%4.34%1.09%1 Year Performance-10.62%-6.12%44.12%23.84% IM Cannabis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCCIM Cannabis1.1993 of 5 stars$2.44+8.0%N/A-23.3%$12.81M$39.44M-4.52340Positive NewsGap UpQNTMQuantum BiopharmaN/A$18.03-12.5%N/AN/A$52.47MN/A-1.29N/AATNMActinium Pharmaceuticals2.4213 of 5 stars$1.65-3.5%$4.50+172.7%-11.6%$51.47MN/A-1.1930UNCYUnicycive Therapeutics2.6896 of 5 stars$4.07-0.2%$60.00+1,374.2%+19.8%$51.45M$680K-0.999Trending NewsHigh Trading VolumeANVSAnnovis Bio1.9753 of 5 stars$2.60-3.4%$18.00+592.6%-74.0%$50.66MN/A-1.273PRLDPrelude Therapeutics3.2364 of 5 stars$0.89-5.4%$4.00+347.8%-76.5%$50.56M$7M-0.54120Positive NewsSLGLSol-Gel Technologies0.7566 of 5 stars$17.74+10.2%N/A+229.7%$49.42M$23.93M-14.4250Gap UpSTTKShattuck Labs3.5217 of 5 stars$1.03+1.0%$7.00+579.6%-71.6%$49.34M$5.72M-0.85100VTVTvTv Therapeutics2.0971 of 5 stars$15.24-1.3%$35.50+133.0%-2.3%$48.68M$17K-4.889Positive NewsHigh Trading VolumeMAAQMana Capital AcquisitionN/A$3.72+2.5%N/A+829.8%$48.67MN/A0.001ABVCABVC BioPharma0.4449 of 5 stars$2.85-8.9%N/A+319.7%$48.40M$391.24K-16.7630 Related Companies and Tools Related Companies QNTM Competitors ATNM Competitors UNCY Competitors ANVS Competitors PRLD Competitors SLGL Competitors STTK Competitors VTVT Competitors MAAQ Competitors ABVC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCC) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IM Cannabis Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share IM Cannabis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access